Moreover, in animal models with renal-targeted deletion of G6Pase, early-onset nephropathy was observed [5], with an increase in oxidative stress levels due to the activation of the angiotensin II and TGF-b1 pathways [6]. Here, G6PC1 is linked to kidney disorder.